LONGEVA.

ACE-083: adverse events and evidence limits

Local intramuscular ACE-083 in adults with facioscapulohumeral muscular dystrophy produced local reactions, myalgia and swelling. Investigators considered a peroneal nerve injury with improving but persistent weakness probably treatment-related. [1]

Related events prompted some withdrawals. Without complete tables, frequencies were not calculated; these findings do not establish systemic-use safety. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Local reactions at the injection siteAdults with facioscapulohumeral muscular dystrophy, local intramuscular administrationDescribed without a frequency; the publication gives no complete frequency tables[1]
MyalgiaThe same participantsDescribed without a frequency[1]
SwellingThe same participantsDescribed without a frequency[1]
Peroneal nerve injury with persistent weaknessThe same participantsInvestigators considered it probably treatment-related; no frequency given[1]
Withdrawals due to related eventsThe same participantsSome related events prompted withdrawals; frequencies were not calculated[1]

References

  1. Jeffrey M Statland et al. (2022). Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy https://doi.org/10.1002/mus.27558.